SAINT LAURENT, QUEBEC--(Marketwire - March 10, 2010) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") today announced that the U.S. Patent and Trademark Office ("USPTO") issued patent number 7,674,479 on March 9, 2010 for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of Bupropion hydrochloride ("HCl"), the active ingredient in Wellbutrin XL®. ... Read More